-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

SCI-10 Bioengineering Strategies to Phenotypically Define Minimal Residual Disease

Program: Scientific Program
Session: Getting the Most from Minimal Residual Disease
Hematology Disease Topics & Pathways:
bioengineering, Technology and Procedures
Sunday, December 6, 2020, 1:55 PM-2:00 PM

Scott R. Manalis, PhD

Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA

Disclosures: Manalis: Affinity Biosensors: Current equity holder in private company; Travera: Consultancy, Current equity holder in private company.

See more of: Getting the Most from Minimal Residual Disease
See more of: Scientific Program
<< Previous Presentation | Next Presentation